Cancer treatment runs in parallel with advanced scientific research. FICAN West is the second largest cancer research center in Finland. Its mission is to coordinate cancer research and teaching in the entire West-coast area.
We promote cancer research and the use of up-to-date scientific data within FICAN West and in the whole of Finland.
The Turku Clinical Research Center provides services in the field of health scientific research for researchers of the University of Turku and the Turku special responsibility area.
This takes you to the web page of the Turku Clinical Research centre
Glossary
Special terms are needed when clinical trials are discussed. Laaketutkimukset.fi-website (in Finnish) contains explanations of the most common terms used in clinical trials.
| STUDY CENTER AND PRINCIPAL INVESTIGATOR | STUDY CODE | TITLE OF THE STUDY |
|---|
| GYNECOLOGICAL CANCER | ||
|---|---|---|
| TUCH / Sakari Hietanen | FIRST | A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer |
| TUCH / Sakari Hietanen | ENGOT –EN2-DGCG | Randomized multicenter trial on the risk of recurrence for patients with cancer limited to the uterus. After surgery, adjuvant treatment or follow-up. |
| TUCH / Sakari Hietanen | DUO-O | A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients |
| TUCH / Sakari Hietanen | RUBY | A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer |
| TUCH / Sakari Hietanen | POD1UM-101 | A phase 1 study of safety, tolerability and pharmacokinetics of INCMGA00012 in patients with advanced solid tumors |
| LYMPHOMA | ||
|---|---|---|
| TUCH / Sirkku Jyrkkiö | Bio-CHIC | Biomarker driven dose intensified chemoimmunotherapy with early CNS profylaxis |
| TUCH / Sirkku Jyrkkiö | TRIANGLE | Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
| BREAST CANCER | ||
|---|---|---|
| TUCH/ Riikka Huovinen ja Vaasa Central Hospital / Antti Jekunen | BOLD | A randomized phase III study compairing trastuzumab,pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive breast cancer |
| TUCH/ Marjaana Luukkaa | SKAGEN | Moderately hypofractionated loco-regional adjuvant radiation therapy of early breast cancer combined with a simultaneous integrated boost in patients with an indication for boost |
| TUCH/ Pia Vihinen | IMpassion132 | A phase III, randomized, double-blind, placebo-controlled, multicentre study of the efficacy and safety of atezolizumab plus chemotherapy for patients with early relapsing recurrent triple-negative breast cancer |
| CRST + TUCH / Pia Vihinen | 1280.18 | An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts |
| Vaasa Central Hospital / Antti Jekunen | CO41101 | A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer |
| UROLOGICAL CANCER | ||
|---|---|---|
| TUCH / Peter Boström | KEYNOTE-057 | Open clinical trial to assess the efficacy and safety of pembrolizumab (MK-3475) in the treatment of patients with cancer of the superficial layer of the urinary bladder and in whom treatment with BCG (Bacillus Calmette Guerin) is no longer efficacious or who do not tolerate such treatment |
| TUCH / Peter Boström | FINNBLADDER 9 | Treatment of stage Ta cancer of the urinary bladder with a high risk of relapse – blue-light cystoscopy and optimized dosage of mitomycin-C. |
| TUCH / Peter Boström | FINNBLADDER 10 | Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma. |
| TUCH / Peter Boström | TALAPRO-2 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER |
| TUCH / Peter Boström | SPCG-15 | Surgery or radiation therapy in the treatment of locally advanced prostate cancer – open, randomized clinical trial. |
| TUCH / Peter Boström | CA017-078 | A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer |
| TUCH / Roberto Blanco | HIFU-PRO | A early phase 1 non-randomized prospective single-institutional and four arm study to determine the applicability, feasibility and safety of MRI guided transurethral HIFU ablation of prostate separately in each pre-specified group/arm |
| TUCH / Peter Boström | PRO-TULSA-PCA | Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-guided Transurethral Ultrasound Ablation for Localized Prostate Cancer |
| TUCH / Peter Boström | ADTPSMA2 | The Effect of Androgen Deprivation Therapy on the Expression of Prostate Specific Membrane Antigen (PSMA) Evaluated With 18F-PSMA PET/CT in Treatment naïve Metastatic Prostate Cancer Patients |
| TUCH / Kalle Mattila | COSMIC-313 | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk |
| TUCH / Kalle Mattila | KEYNOTE-991 | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
| TUCH / Kalle Mattila | MK6482-005 | An Open-label,Randomized Phase 3 Study of MK-6482 Versus Everolimus in participants with Advanced Renal Cell Carcinoma that has progressed after prior PD-1/L1 and VEGFR Tyrosine Kinase Inhibitor Therapy |
| TUCH / Kalle Mattila | NEKTAR | A phase 3, randomized, open-label Study of NKTR-214 combined with nivolumab versus Nivolumab in participants with previously untreated unresectable or metastatic melanoma |
| HEAD AND NECK CANCER | ||
|---|---|---|
| TUCH / Heikki Minn | HNLB | Genetic Profiling by Liquid Biopsy for Initial Characterization and Response Monitoring of Head and Neck Squamous Cell Carcinoma |
| HEMATOLOGICAL CANCER | ||
|---|---|---|
| TUCH / Mervi Putkonen | NMSG 23/15 | A Prospective phase 2 study to assess the minimal residual disease after ixazomib plus lenalidomide and dexamethasone (IRd) treatment for newly diagnosed transplant eligible myeloma patients |
| TUCH / Pia Ettala | Ponatinib-3001 | A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) |
| TUCH / Maija Itälä-Remes | HaploMUDStudy | Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis – A Randomized Prospective European Trial. |
| PALLIATIVE |
|---|
| GASTROINTESTINAL CANCER | ||
|---|---|---|
| Satasairaala Hospital / Kalevi Pulkkanen | SSGXXII | Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence |
| TUCH / Pirita Varpe | RESET | Laparotomy vs Laparoscopy vs Robotic vs TaTME Rectal Surgery Matched Parallel Cohort Trial for High Surgical Risk Cancer Patients, With Mid- to Low Rectal Cancer |
| MELANOMA | ||
|---|---|---|
| TUCH / Pia Vihinen | CA224-047 | A randomized, double-blind phase 2/3 study of relatlimab combined with nivolumab versus nivolumab in participants with previously untreated metastatic or unresectable melanoma |
| TUCH / Kalle Mattila | CA209-76K | A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma |
| LUNG CANCER | ||
|---|---|---|
| TUCH / Maria Silvoniemi and Vaasa Central Hospital / Antti Jekunen | ASTEROID | Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An Open Label Randomized Phase II Trial With Durvalumab Following Stereotactic Body Radiotherapy (SBRT) in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) |
| TUCH / Maria Silvoniemi | 20190294 | A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer |
| TUCH / Maria Silvoniemi | 20190009 | A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C |
| OTHER | ||
|---|---|---|
| TUCH / Kalle Mattila | Predictive clinical, imaging and laboratory biomarkers of cardiac toxicity related to anti-programmed death (PD)-1 therapies | |
| TUCH / Pia Vihinen | COVID-19 and cancer | Impact of COVID-19 infections on cancer patients: prospective, observational multicenter study |
| PEDIATRIC | ||
|---|---|---|
| TUCH / Päivi Lähteenmäki | IntreALL 2010SR | International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010. A randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group |
| TUCH / Päivi Lähteenmäki | NOPHo-DBH AML 2012 | Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years |
| TUCH / Päivi Lähteenmäki | EURO-Ewing 2008 | A randomised trial for patients with localised or metastatic Ewing sarcomas |
| TUCH / Päivi Lähteenmäki | NOPHO ALL2008 | Treatment Protocol for Children (1.0 – 17.9 years of age) and young adults (18-45 years of age) with Acute Lymphoblastic Leukemia. |
| TUCH / Päivi Lähteenmäki | SIOP PNET 5-MB | AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB – LR) OR AVERAGE-RISK BIOLOGICAL PROFILE |
| TUCH / Päivi Lähteenmäki | Einstein 14372 | Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism. EINSTEIN Junior Phase III: oral rivaroxaban in children with venous thrombosis |
| TUCH / Miia Mokka | TEDDI | Radiotherapy Delivery in Deep Inspiration for Pediatric Patients |
